Cargando…

Enhanced germinal center reaction by targeting vaccine antigen to major histocompatibility complex class II molecules

Enhancing the germinal center (GC) reaction is a prime objective in vaccine development. Targeting of antigen to MHCII on APCs has previously been shown to increase antibody responses, but the underlying mechanism has been unclear. We have here investigated the GC reaction after targeting antigen to...

Descripción completa

Detalles Bibliográficos
Autores principales: Andersen, Tor Kristian, Huszthy, Peter C., Gopalakrishnan, Ramakrishna P., Jacobsen, Johanne T., Fauskanger, Marte, Tveita, Anders A., Grødeland, Gunnveig, Bogen, Bjarne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370881/
https://www.ncbi.nlm.nih.gov/pubmed/30775000
http://dx.doi.org/10.1038/s41541-019-0101-0
_version_ 1783394448619601920
author Andersen, Tor Kristian
Huszthy, Peter C.
Gopalakrishnan, Ramakrishna P.
Jacobsen, Johanne T.
Fauskanger, Marte
Tveita, Anders A.
Grødeland, Gunnveig
Bogen, Bjarne
author_facet Andersen, Tor Kristian
Huszthy, Peter C.
Gopalakrishnan, Ramakrishna P.
Jacobsen, Johanne T.
Fauskanger, Marte
Tveita, Anders A.
Grødeland, Gunnveig
Bogen, Bjarne
author_sort Andersen, Tor Kristian
collection PubMed
description Enhancing the germinal center (GC) reaction is a prime objective in vaccine development. Targeting of antigen to MHCII on APCs has previously been shown to increase antibody responses, but the underlying mechanism has been unclear. We have here investigated the GC reaction after targeting antigen to MHCII in (i) a defined model with T and B cells of known specificity using adjuvant-free vaccine proteins, and (ii) an infectious disease model using a DNA vaccine. MHCII-targeting enhanced presentation of peptide: MHCII on APCs, and increased the numbers of GC B cells, T(FH), and plasma cells. Antibodies appeared earlier and levels were increased. BCR of GC B cells and serum antibodies had increased avidity for antigen. The improved responses required cross-linking of BCR and MHCII in either cis or trans. The enhanced GC reaction induced by MHCII-targeting of antigen has clear implications for design of more efficient subunit vaccines.
format Online
Article
Text
id pubmed-6370881
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-63708812019-02-15 Enhanced germinal center reaction by targeting vaccine antigen to major histocompatibility complex class II molecules Andersen, Tor Kristian Huszthy, Peter C. Gopalakrishnan, Ramakrishna P. Jacobsen, Johanne T. Fauskanger, Marte Tveita, Anders A. Grødeland, Gunnveig Bogen, Bjarne NPJ Vaccines Article Enhancing the germinal center (GC) reaction is a prime objective in vaccine development. Targeting of antigen to MHCII on APCs has previously been shown to increase antibody responses, but the underlying mechanism has been unclear. We have here investigated the GC reaction after targeting antigen to MHCII in (i) a defined model with T and B cells of known specificity using adjuvant-free vaccine proteins, and (ii) an infectious disease model using a DNA vaccine. MHCII-targeting enhanced presentation of peptide: MHCII on APCs, and increased the numbers of GC B cells, T(FH), and plasma cells. Antibodies appeared earlier and levels were increased. BCR of GC B cells and serum antibodies had increased avidity for antigen. The improved responses required cross-linking of BCR and MHCII in either cis or trans. The enhanced GC reaction induced by MHCII-targeting of antigen has clear implications for design of more efficient subunit vaccines. Nature Publishing Group UK 2019-02-11 /pmc/articles/PMC6370881/ /pubmed/30775000 http://dx.doi.org/10.1038/s41541-019-0101-0 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Andersen, Tor Kristian
Huszthy, Peter C.
Gopalakrishnan, Ramakrishna P.
Jacobsen, Johanne T.
Fauskanger, Marte
Tveita, Anders A.
Grødeland, Gunnveig
Bogen, Bjarne
Enhanced germinal center reaction by targeting vaccine antigen to major histocompatibility complex class II molecules
title Enhanced germinal center reaction by targeting vaccine antigen to major histocompatibility complex class II molecules
title_full Enhanced germinal center reaction by targeting vaccine antigen to major histocompatibility complex class II molecules
title_fullStr Enhanced germinal center reaction by targeting vaccine antigen to major histocompatibility complex class II molecules
title_full_unstemmed Enhanced germinal center reaction by targeting vaccine antigen to major histocompatibility complex class II molecules
title_short Enhanced germinal center reaction by targeting vaccine antigen to major histocompatibility complex class II molecules
title_sort enhanced germinal center reaction by targeting vaccine antigen to major histocompatibility complex class ii molecules
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370881/
https://www.ncbi.nlm.nih.gov/pubmed/30775000
http://dx.doi.org/10.1038/s41541-019-0101-0
work_keys_str_mv AT andersentorkristian enhancedgerminalcenterreactionbytargetingvaccineantigentomajorhistocompatibilitycomplexclassiimolecules
AT huszthypeterc enhancedgerminalcenterreactionbytargetingvaccineantigentomajorhistocompatibilitycomplexclassiimolecules
AT gopalakrishnanramakrishnap enhancedgerminalcenterreactionbytargetingvaccineantigentomajorhistocompatibilitycomplexclassiimolecules
AT jacobsenjohannet enhancedgerminalcenterreactionbytargetingvaccineantigentomajorhistocompatibilitycomplexclassiimolecules
AT fauskangermarte enhancedgerminalcenterreactionbytargetingvaccineantigentomajorhistocompatibilitycomplexclassiimolecules
AT tveitaandersa enhancedgerminalcenterreactionbytargetingvaccineantigentomajorhistocompatibilitycomplexclassiimolecules
AT grødelandgunnveig enhancedgerminalcenterreactionbytargetingvaccineantigentomajorhistocompatibilitycomplexclassiimolecules
AT bogenbjarne enhancedgerminalcenterreactionbytargetingvaccineantigentomajorhistocompatibilitycomplexclassiimolecules